CD68 and neoplasm: The results demonstrated that mCRC patients who benefit more from sintilimab plus anlotinib often exhibit greater infiltration of immune cells, including PD-1+ CD8+ T cells, PD-L1+ CD68+ macrophages, CD20+ B cells, and CD56dim NK cells, into the tumor microenvironment.